Table 2 Cox regression analysis of baseline hsCRP categories and hypertension status for predicting cardiovascular outcomes

From: High-sensitivity C-reactive protein and hypertension: combined effects on coronary severity and cardiovascular outcomes

 

Hazards ratio (95% CI)

 

Unadjusted model

Model 1

Model 2

All endpoint events

   HsCRP levels (Events/Subjects)

      <1 mg/La (162/1520)

1.00

1.00

1.00

      1–3 mg/L (218/1709)

1.17 (0.95–1.43)

1.16 (0.95–1.43)

1.02(0.82–1.25)

      >3 mg/L (150/1062)

1.30 (1.04–1.62)b

1.29 (1.03–1.61)b

1.14(0.90–1.43)

      Hypertension

1.46 (1.21–1.76)c

1.39 (1.15–1.68)c

1.31 (1.08–1.60)c

Hard endpoint events

   HsCRP levels (Events/Subjects)

      <1 mg/La (59/1520)

1.00

1.00

1.00

      1–3 mg/L (86/1709)

1.23 (0.88–1.71)

1.22 (0.88–1.70)

1.00 (0.71–1.42)

      >3 mg/L (73/1062)

1.71 (1.21–2.41)c

1.68 (1.19–2.36)c

1.40 (0.98–2.00)

      Hypertension

1.65 (1.22–2.23)c

1.50 (1.11–2.04)c

1.47 (1.06–2.02)b

  1. Model 1, age-adjusted and sex-adjusted. Model 2 included age, sex, current smoking, diabetes mellitus, hypertension, hsCRP categories, Gensini score, left ventricular ejection fraction, triglyceride, low-density lipoprotein cholesterol, statin use (Yes or No) and antihypertensive drugs use (Yes or No). HsCRP high-sensitivity C-reactive protein
  2. aReference group
  3. bp < 0.05
  4. cp < 0.01